Kevin Patrick Danahy - Jul 3, 2024 Form 4 Insider Report for PULSE BIOSCIENCES, INC. (PLSE)

Role: Chief Commercial Officer
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol: PLSE
Transactions as of: Jul 3, 2024
Transactions value $: $0
Form type: 4
Date filed: 7/9/2024, 09:12 AM
Previous filing: Nov 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLSE	Common Stock	Exercise of in-the-money or at-the-money derivative security		+650	+1.81%		36.5K	Jul 3, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Warrant (right to buy)	Purchase		+325			325	Jul 3, 2024	Common Stock	325	$11.00	Direct	F1, F2
transaction	PLSE	Warrant (right to buy)	Purchase		+325			325	Jul 3, 2024	Common Stock	325	$11.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC.
F2	Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions.